Anil Narasimha is the co-founder and CEO of Mekonos. He is a scientist by training, having done his graduate work at UC San Diego and a postdoctoral fellowship with Dr. Michael Snyder at Stanford University. His expertise lies in enabling technologies in cell and gene therapy, and he co-founded Mekonos in hopes of making delivery of molecules more efficient, precise, and automated.
Emerging Therapeutics Showcase:
Mekonos is an enabling technology company developing a platform for ex-vivo delivery of molecules into cells.
Ex-vivo Delivery of Payloads into Cells using Silicon Technology
Mekonos is a Series A company developing a platform for precise delivery of payloads into cells.
Session Abstract – PMWC 2023 Silicon Valley
The PMWC 2023 Emerging Therapeutics Showcase will provide a 15-minute time slot for selected companies and researchers in the CRISPR, Cell and Gene Therapy fields. Major advancements in safer cell- and gene-level editing technologies are bringing us closer toward cures for life-threatening disorders, from cancer to HIV to Huntington’s disease. Cell therapy, in which cellular material such as T cells capable of fighting cancer cells, is injected into a patient, has been demonstrated safe and effective. The popular new CRISPR tool that has been used to edit the genetic code of nearly any organism will have an enormous impact on human health. More than a dozen clinical trials employing CRISPR on human cells are already underway.
- Emerging Therapeutics/Cell Therapy
- Emerging Therapeutics/CVD
- Emerging Therapeutics/Gene Therapy
- Emerging Therapeutics/Immunotherapy
- Emerging Therapeutics/Radiation Therapy